ProPhase Labs
Biotechnology, Healthcare, Pharmaceutical · 96 employees
ProPhase Labs, Inc. is a pharmaceutical company specializing in pharmaceutical preparations. The company is currently undergoing strategic shifts and growth initiatives to navigate potential challenges while capitalizing on significant market opportunities.
Funding history
- Series seed — $3.0M — Aug 2025
- Series seed — $1.0M — Jul 2025
- Funding Round — $1.5M — Dec 2015
Recent signals
- Oct 09, 2025: SEC 8-K (1.01): On October 9, 2025, ProPhase Labs, Inc. entered into an At-the-Market Sales Agreement with WestPark Capital, Inc. as the sales agent. This agreement allows the company to offer and sell shares of its common stock over time, utilizing their existing Registration Statement on Form S-3 (File No. 333-283182), which was declared effective by the SEC on November 20, 2024. The financial implications of this agreement involve the potential for ProPhase Labs to raise capital through the sale of its common stock, enhancing its liquidity and ability to fund operations or growth strategies, although specific financial amounts for the shares sold were not detailed in the filing.
- Aug 05, 2025: Raised $3.0M in Series seed
- Jul 07, 2025: Raised $1.0M in Series seed
- Dec 28, 2015: Raised $1.5M
See plans & pricing → Track ProPhase Labs’s funding, hiring, and signals — with verified contacts — on Fundz.